Filing Details

Accession Number:
0001209191-17-015520
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-02-28 19:33:09
Reporting Period:
2017-02-24
Filing Date:
2017-02-28
Accepted Time:
2017-02-28 19:33:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1513818 Versartis Inc. VSAR Pharmaceutical Preparations (2834) 264106690
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1528826 T Joshua Brumm C/O Versartis, Inc.
4200 Bohannon Drive, Suite 250
Menlo Park CA 94025
Coo And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-02-24 30,000 $2.53 135,779 No 4 M Direct
Common Stock Disposition 2017-02-24 18,339 $20.42 117,440 No 4 S Direct
Common Stock Disposition 2017-02-24 6,008 $21.46 111,432 No 4 S Direct
Common Stock Disposition 2017-02-24 5,653 $22.05 105,779 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-02-24 30,000 $0.00 30,000 $2.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
122,108 2023-12-04 No 4 M Direct
Footnotes
  1. Shares sold pursuant to a 10b5-1 trading plan.
  2. The shares were sold at prices ranging from $19.90 to $20.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each price.
  3. The shares were sold at prices ranging from $20.90 to $21.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each price.
  4. The shares were sold at prices ranging from $21.90 to $22.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each price.
  5. Twenty-Five percent of the shares subject to the option became exercisable one year from 11/12/2013; the remainder become exercisable in equal monthly installments over the following three years.